Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand

<p>Abstract</p> <p>Background</p> <p>This study aims to determine the maximum price at which HIV vaccination is cost-effective in the Thai healthcare setting. It also aims to identify the relative importance of vaccine characteristics and risk behavior changes among vaccine recipients to determine how they affect this cost-effectiveness.</p> <p>Methods</p> <p>A semi-Markov model was developed to estimate the costs and health outcomes of HIV prevention programs combined with HIV vaccination in comparison to the existing HIV prevention programs without vaccination. The estimation was based on a lifetime horizon period (99 years) and used the government perspective. The analysis focused on both the general population and specific high-risk population groups. The maximum price of cost-effective vaccination was defined by using threshold analysis; one-way and probabilistic sensitivity analyses were performed. The study employed an expected value of perfect information (EVPI) analysis to determine the relative importance of parameters and to prioritize future studies.</p> <p>Results</p> <p>The most expensive HIV vaccination which is cost-effective when given to the general population was 12,000 Thai baht (US$1 = 34 Thai baht in 2009). This vaccination came with 70% vaccine efficacy and lifetime protection as long as risk behavior was unchanged post-vaccination. The vaccine would be considered cost-ineffective at any price if it demonstrated low efficacy (30%) and if post-vaccination risk behavior increased by 10% or more, especially among the high-risk population groups. The incremental cost-effectiveness ratios were the most sensitive to change in post-vaccination risk behavior, followed by vaccine efficacy and duration of protection. The EVPI indicated the need to quantify vaccine efficacy, changed post-vaccination risk behavior, and the costs of vaccination programs.</p> <p>Conclusions</p> <p>The approach used in this study differentiated it from other economic evaluations and can be applied for the economic evaluation of other health interventions not available in healthcare systems. This study is important not only for researchers conducting future HIV vaccine research but also for policy decision makers who, in the future, will consider vaccine adoption.</p

Spending of HIV resources in Asia and Eastern Europe: systematic review reveals the need to shift funding allocations towards priority populations

Introduction: It is increasingly important to prioritize the most cost-effective HIV interventions. We sought to summarize the evidence on which types of interventions provide the best value for money in regions with concentrated HIV epidemics. Methods: We conducted a systematic review of peer-reviewed and grey literature reporting measurements of cost-effectiveness or cost-benefit for HIV/AIDS interventions in Asia and Eastern Europe. We also collated HIV/AIDS spending assessment data from case-study countries in the region. Results: We identified 91 studies for inclusion, 47 of which were from peer-reviewed journals. Generally, in concentrated settings, prevention of mother-to-child transmission programmes and prevention programmes targeting people who inject drugs and sex workers had lower incremental cost-effectiveness ratios than programmes aimed at the general population. The few studies evaluating programmes targeting men who have sex with men indicate moderate cost-effectiveness. Collation of prevention programme spending data from 12 countries in the region (none of which had generalized epidemics) indicated that resources for the general population/non-targeted was greater than 30% for eight countries and greater than 50% for five countries. Conclusions: There is a misalignment between national spending on HIV/AIDS responses and the most affected populations across the region. In concentrated epidemics, scarce funding should be directed more towards most-at-risk populations. Reaching consensus on general principles of cost-effectiveness of programmes by epidemic settings is difficult due to inconsistent evaluation approaches. Adopting a standard costing, impact evaluation, benefits calculation, analysis and reporting framework would enable cross comparisons and improve HIV resource prioritization and allocation.Andrew P Craig, Hla-Hla Thein, Lei Zhang, Richard T Gray, Klara Henderson, David Wilson, Marelize Gorgens, and David P Wilso

Provider-initiated HIV/AIDS counselling and testing at healthcare facilities in Thailand: a cluster-randomisation trial

The World Health Organization and UNAIDS advocate that healthcare providers worldwide consider provider-initiated HIV counselling and testing for clients attending healthcare facilities. However, there is a lack of evidence needed to support policy decisions, concerning the effectiveness of such interventions in Thailand and other settings with large outbreaks of the HIV epidemic. As a result, a cluster-randomisation trial with pre-test and post-test design was conducted to assess the effectiveness of healthcare provider-initiated voluntary HIV counselling and testing compared with the current practice in which HIV testing is provided only upon the client's request. Sixteen district hospitals (clusters) with high and low HIV prevalence were randomly assigned to either use the new intervention or to continue with the current practice with a 1:1 allocation ratio. Patients aged between 13 and 64 years, receiving ambulatory care in the participating hospitals, were eligible. The main outcome measures were the acceptance rate of HIV testing and the HIV detection rate. During the first eight-week baseline period, there were no significant differences between the control and experimental clusters on the acceptance rate and HIV detection. However, after the eight-week intervention period, the acceptance rate and HIV detection rate in the experimental clusters was significantly higher than those of the control clusters. The results from the generalised estimating equations and multilevel modelling also confirmed the findings. Economic appraisal alongside this study suggested that the new intervention is very cost-effective under the Thai healthcare setting.HIV/AIDS, counselling and testing, provider-initiated HIV counselling and testing, cluster-randomised trial, Thailand,